Mississippi has one of the highest death rates from cancer in the United States. While theincidence of cancer in Mississippi is somewhat normal, death from it is much higher. Each day, the Cancer Institute employees work to enable more people to survive cancer. The Cancer Institute is home to the ACT Tobacco Treatment, Education and Research program that provides medication and counseling to help Mississippians quit using tobacco, a risk factor in dozens of cancers. The Cancer Institute, through University Cancer Care, its medical arm, also provides screening for multiple cancers in hopes of finding cancer early when chances of successful treatment are highest. Cancer Institute researchers work with about 20 graduate and post-doctoral students to find new ways to stop cancer. Researchers search for genetic links that will help families, for new targets for medication and working with the Cancer Drug Discovery Core at the National Center for Natural Products Research in Oxford, they search for new drugs that will attack cancer’s weak link.
Pediatric hematology care at Children's of Mississippi incorporates a team of medical, surgical, radiotherapy and pathology subspecialists as well as supporting nursing, laboratory and social work personnel. The Pediatric Hematology/Oncology faculty at the University of Mississippi Medical Center treat children with cancer and blood disorders, providing the best in patient care and advances in diagnosis and treatment to the children of Mississippi and surrounding states. They are active members of the Children's Oncology Group, the world's largest children's cancer research collaborative with more than 210 member hospitals, and participate in clinical research protocols aimed at improving the lives of children with cancer and blood disorders and advancing future treatments and outcomes.
The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative uses comprehensive molecular characterization to determine the molecular changes that drive the initiation and progression of some childhood cancers. TARGET aims to identify prognostic markers and therapeutic targets of hard-to-treat childhood cancers so that new, more effective treatment strategies can be developed. Through a large, diverse collaborative network among NIH/NCI intramural and extramural investigators, TARGET accelerates the generation of high quality genomic data and the translation of those findings into the clinic. TARGET data is readily available to the research community for further investigation to facilitate new discoveries in pediatric cancer research.
The Children’s Oncology Group (COG), a National Cancer Institute supported clinical trials group, is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 8,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer. The COG, with more than 7,500 experts worldwide, has nearly 100 active clinical-translational trials open at any given time. These trials include front-line treatment for many types of childhood cancers, studies aimed at determining the underlying biology of these diseases, and trials involving new and emerging treatments, supportive care, and survivorship. COG’s research studies encompass hematologic malignancies, solid tumors, central nervous system tumors and rare cancers.
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005